Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BARD C R INC /NJ/BCR · Entity 170698 | Director | December 29, 2017 | January 03, 2018 |
| CEL SCI CORPCVM · Entity 7495 | Director | August 08, 2023 | August 10, 2023 |
| CERENOME, INC.CTYX · Entity 7637 | Director | November 28, 2017 | November 29, 2017 |
| Histogen Inc.HSTO · Entity 112047 | See Remarks | January 13, 2021 | January 15, 2021 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | November 03, 2025 | November 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BARD C R INC /NJ/
Report date December 29, 2017 · Filed January 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 1
1 source rowRow 1 · 2017-12-29 · Disposition to issuer · Disposed 1,922.6298 · Balance 0 F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). |
| Share Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-29 · Disposition to issuer · Disposed 9,516 · Balance 0 F2: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3: Conversion is 1 for 1. F4: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").
F2: Units granted under the Company's Stock Equivalent Plan for Outside Directors.
F3: Conversion is 1 for 1.
F4: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.
CEL SCI CORP
Report date August 08, 2023 · Filed August 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2033-08-07 | Direct | 149,000 |
Reported balance
After 2023-08-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-08 · Grant · Acquired 85,000 · Balance 149,000 F1: The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in three (3) equal annual installments commencing one year after the grant date.
CERENOME, INC.
Report date November 28, 2017 · Filed November 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Subscription Rights (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2017-11-21 | Direct | 0 |
Reported balance
After 2017-11-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-28 · Other · Disposed 1 · Balance 0 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. |
| Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.33 | Direct | 1 |
Reported balance
After 2017-11-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-28 · Other · Acquired 1 · Balance 1 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2: The Series B Preferred Stock has no expiration date. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2020-05-28 | Direct | 1,800 |
Reported balance
After 2017-11-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-28 · Other · Acquired 1,800 · Balance 1,800 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.
F2: The Series B Preferred Stock has no expiration date.
F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020.
Histogen Inc.
Report date January 13, 2021 · Filed January 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2031-01-13 | Direct | 95,000 |
Reported balance
After 2021-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-13 · Grant · Acquired 95,000 · Balance 95,000 F1: 1/4 of the shares subject to the option vest one year after the date of grant, on 1/13/2022, and the remaining 1/36 of the shares vest on a monthly basis thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4 of the shares subject to the option vest one year after the date of grant, on 1/13/2022, and the remaining 1/36 of the shares vest on a monthly basis thereafter.
TherapeuticsMD, Inc.
Report date November 03, 2025 · Filed November 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,500 |
Reported balance
After 2025-11-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-03 · Grant · Acquired 8,500 · Balance 8,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2025 Filed Nov 5, 2025 21:17 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-003784 · form4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000739 · form4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:07 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000739 · form4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:53 UTC | CEL SCI CORP CVM · Entity 7495 | GrantOptions · Derivative | 85,000 | $0.01 Strike: $1.36 | $850.00 |
DisclosureSEC source: 0001236030-23-000014 · primary_doc.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,000 Underlying: Common Stock · 85,000 shares Expires 2033-08-07 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:28 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Unit · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042765 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 01:10 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 3,922 | $5.26 | $20,635.21 |
DisclosureSEC source: 0001209191-22-060424 · doc4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 22:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051960 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 1,984 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046968 · doc4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,984 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on July 1, 2022. F3 · derivative.expiration_date: The RSUs vested on July 1, 2022. F1 · derivative.underlying_shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 1,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046968 · doc4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:39 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-008441 · ownership.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on June 18, 2021. F3 · derivative.expiration_date: The RSUs vested on June 18, 2021. F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · derivative.underlying_shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:39 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 96,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-008441 · ownership.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:04 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 99,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007131 · ownership.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,174 Underlying: Common Stock · 99,174 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 16:14 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001209191-21-003758 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-01-13 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest one year after the date of grant, on 1/13/2022, and the remaining 1/36 of the shares vest on a monthly basis thereafter. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 21:10 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-005819 · ownership.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,864 Underlying: Common Stock · 96,864 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. Read SEC document |
| May 26, 2020 Filed May 28, 2020 19:55 UTC | Histogen Inc. HSTO · Entity 112047 | OtherCommon Stock | 426,526 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014479 · doc4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 426,526 F1 · timeliness: Shares of common stock of the corporation formerly known as Histogen Inc. ("Histogen") were converted into shares of common stock of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of January 28, 2020, by and among the Issuer, Chinook Merger Sub, Inc. and Histogen (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Histogen common stock was exchanged for 1.4342 shares of the Issuer's common stock (the "Conversion"). Immediately following the merger, the Issuer changed its name to Histogen Inc. All share numbers reflect the one-for-ten reverse stock split (the "Reverse Split") effected by the Issuer immediately prior to the completion of the merger. F2 · ownership.nature: Shares held by the Gail K. Naughton Revocable Trust, dated January 19, 2018. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:33 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | Disposition to issuerShare Equivalent Units · Derivative | 9,516 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-18-000469 · doc4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,516 shares Expires not disclosed F2 · security: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F3 · derivative.exercise_price: Conversion is 1 for 1. F4 · price: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. F4 · derivative.exercise_date: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. F4 · derivative.expiration_date: These units, which are 100% vested, were assumed by BD at the effective time of the Merger. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:33 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | Disposition to issuerCommon Stock | 1,922.6298 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000469 · doc4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration"). Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 15:05 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantShare Equivalent Units · Derivative | 245 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018191 · doc4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,516 Underlying: Common Stock · 245 shares Expires not disclosed F3 · security: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F4 · derivative.exercise_price: Conversion is 1 for 1. F5 · derivative.exercise_date: Share Equivalent Units are settled in cash upon termination as a director. F5 · derivative.expiration_date: Share Equivalent Units are settled in cash upon termination as a director. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 15:05 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 298 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018191 · doc4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,922.6298 F1 · kind: Stock award granted in accordance with the 2005 Directors' Stock Award Plan, as amended and restated, that fully vests in three years from the date of grant, subject to earlier acceleration. F2 · balance_after: Includes 4.87 shares acquired under the Company's Dividend Reinvestment Plan from November 5, 2016 to August 4, 2017. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:39 UTC | CERENOME, INC. CTYX · Entity 7637 | OtherWarrants (Right to Buy) · Derivative | 1,800 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062901 · doc4.xml · derivative · entry 3 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:39 UTC | CERENOME, INC. CTYX · Entity 7637 | OtherSeries B Preferred Stock · Derivative | 1 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062901 · doc4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:39 UTC | CERENOME, INC. CTYX · Entity 7637 | OtherSubscription Rights (Right to Buy) · Derivative | 1 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-062901 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 09:31 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | SaleCommon Stock | 367 | $236.22 | $86,694.21 |
DisclosureSEC source: 0001225208-17-002153 · doc4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,619.7598 F1 · price: Represents the weighted average sales price for price increments ranging from $236.17 to $236.35. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:48 UTC | CERENOME, INC. CTYX · Entity 7637 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005972 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 15:58 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantShare Equivalent Units · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-043312 · doc4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,271 Underlying: Common Stock · 375 shares Expires not disclosed F3 · security: Units granted under the Company's Stock Equivalent Plan for Outside Directors. F4 · derivative.exercise_price: Conversion is 1 for 1. F5 · derivative.exercise_date: Share Equivalent Units are settled in cash upon termination as a director. F5 · derivative.expiration_date: Share Equivalent Units are settled in cash upon termination as a director. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 15:58 UTC | BARD C R INC /NJ/ BCR · Entity 170698 | GrantCommon Stock | 468 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-043312 · doc4.xml · nonDerivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986.7598 F1 · kind: Stock award granted in accordance with the 2005 Directors' Stock Award Plan, as amended and restated, that fully vests in three years from the date of grant. F2 · balance_after: Includes 7.9533 shares acquired under the Company's Dividend Reinvestment Plan from November 7, 2015 to November 4, 2016. Read SEC document |
| May 12, 2012 Filed May 28, 2020 19:55 UTC | Histogen Inc. HSTO · Entity 112047 | OtherStock Option (right to buy) · Derivative | 380,063 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000899243-20-014479 · doc4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,063 Underlying: Common Stock · 380,063 shares Expires 2022-05-12 F3 · derivative.exercise_date: Fully vested. Shares subject to the option and the exercise price have been adjusted based upon the Conversion and Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.